Skip to main content
BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. logo

BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. — Investor Relations & Filings

Ticker · 300289 ISIN · CNE100001C22 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,951 across all filing types
Latest filing 2026-03-30 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300289

About BEIJING LEADMAN BIOCHEMISTRY CO.,LTD.

https://www.leadmanbio.com

Beijing Leadman Biochemistry Co., Ltd. specializes in the research, development, manufacturing, and distribution of in-vitro diagnostic (IVD) solutions. The company’s core portfolio includes a wide range of clinical chemistry reagents, chemiluminescence immunoassay kits, and automated diagnostic instruments. These products support various medical testing areas, such as liver and kidney function, lipid profiles, and cardiac markers. By providing integrated systems that combine high-performance reagents with specialized hardware, the company serves hospitals, clinical laboratories, and medical institutions. Its operations focus on delivering precise and efficient diagnostic tools to enhance clinical decision-making and patient care.

Recent filings

Filing Released Lang Actions
关于2025年度拟不进行利润分配的公告
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement from Beijing Leadman Biochemical Co., Ltd. regarding the company's 2025 annual profit distribution plan, specifically stating that no profit distribution (dividends) will be made due to losses incurred in 2025. It includes details about the board meeting approving the proposal, audited net profit figures, cumulative undistributed profits, and explanations for the decision not to distribute dividends. The document is relatively short (2257 characters) and focuses on the profit distribution plan rather than presenting full financial statements or comprehensive annual report content. It is a formal announcement about the dividend decision rather than the full annual report or earnings release. Therefore, it fits best into the category of Notice of Dividend Amount (DIV), as it announces the dividend policy and payment decision for the fiscal year 2025.
2026-03-30 Chinese
董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors for the year 2025. It references regulatory guidelines about independent directors and confirms their independence status. The content is focused on governance and compliance with independent director requirements, rather than financial results, audit, or management changes. It is not a full report but a board statement on governance matters related to director independence. Therefore, the most appropriate classification is Governance Information (CGR). The document length is short but contains substantive governance content, not just an announcement or certification.
2026-03-30 Chinese
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) issued by 华兴会计师事务所 for 北京利德曼生化股份有限公司. It contains detailed auditor opinions, audit basis, key audit matters, management responsibilities, and auditor responsibilities. It includes comprehensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the fiscal year ending December 31, 2025. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure clearly identify it as a standalone audit report rather than a full annual report or other filing types. Therefore, the correct classification is Audit Report / Information (AR). FY 2025
2026-03-30 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "北京利德曼生化股份有限公司 2025 年年度报告全文" which translates to "Beijing Leadman Biochemical Co., Ltd. 2025 Annual Report Full Text." It contains detailed financial data for the fiscal year 2025, including revenue, net profit, quarterly financial indicators, and management discussion and analysis. The document includes sections such as company overview, main financial indicators, management discussion and analysis, corporate governance, and financial statements. It also contains auditor's report references and signatures from company officers, indicating it is a full official annual report. The length of the document (15,000 characters) and the comprehensive content confirm it is the full annual report, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2025
2026-03-30 Chinese
2025年度独立董事述职报告（安娜）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 by an independent director of Beijing Lideman Biochemical Co., Ltd. It details the director's attendance at meetings, participation in committees, supervision of audits, protection of investor rights, and involvement in major company matters such as asset acquisitions and management appointments. The content focuses on the director's duties, governance, and oversight activities rather than financial results or earnings. It is a detailed report on board/management activities and governance rather than a financial report or announcement. Therefore, the document fits best under the category of Board/Management Information (MANG).
2026-03-30 Chinese
关于举行2025年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online performance explanation meeting (业绩说明会) for the fiscal year 2025. It references that the 2025 Annual Report has already been disclosed on March 31, 2026, and invites investors to participate in the meeting on April 3, 2026. The document does not contain the actual annual report or detailed financial data but rather announces the event to discuss the annual results. The document length is short (912 characters), and it serves as a notice for an investor presentation event related to the annual results. Therefore, it fits best under Investor Presentation (IP) category rather than the Annual Report (10-K) or Report Publication Announcement (RPA).
2026-03-30 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.